Eli Lilly and Co said on Wednesday it had submitted a request to the US Food and Drug Administration for emergency use of its experimental antibody treatment for COVID-19. Separately, the US drugmaker said data from a new study showed a combination of two of its antibody treatments helped reduce hospitalization and emergency room visits for COVID-19 patients.
